Looks like a typical over-reaction to me. Failed both primary and secondary endpoints, did no better than placebo, results even worse than expected, management desperately spinning. Utter and total disaster, not an over-reaction. EDIT: Also this from Twitter, could be even worse than management is letting on- Martin Shkreli ?@MartinShkreli 1h1 hour ago just realized the post-hoc analysis excludes half of the drug group patients. wow. $ATHX